Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00050348.xml
![](/products/assets/desktop/img/oa-logo.png)
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2009; 30(S 01): 16-18
DOI: 10.1055/s-0041-1733328
DOI: 10.1055/s-0041-1733328
Original Article
Neoadjuvant Chemotherapy (NACT) in Advanced Epithelial Ovarian Cancer: International Data and TMH Experience
Publication History
Article published online:
02 March 2022
© 2009. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 The International Collaborative Ovarian Neoplasm (ICON) Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505–515, 2002